Post-market Reviews of Pulmonary Arterial Hypertension medicines and biological Disease Modifying Anti Rheumatic Drugs to treat severe chronic plaque psoriasis

The public consultation process is now open for the following two post-market reviews:

• Pulmonary Arterial Hypertension (PAH) medicines; and
• biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) to treat severe chronic plaque psoriasis.

Interested organisations and individuals are invited to provide a submission addressing the reviews’ Draft Terms of Reference.

To make a submission to either of these reviews, please go to the relevant web page:

1. for PAH Medicines; or
2. for bDMARDs.

Submissions will be accepted from 2 May 2016 until 5pm on 16 May 2016, in line with the Post-market Review Framework.